Received Dec 16, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| UNK | VACCINE NOT SPECIFIED (NO BRAND NAME) | UNKNOWN MANUFACTURER | 1 | — | — |
| UNK | VACCINE NOT SPECIFIED (NO BRAND NAME) | UNKNOWN MANUFACTURER | 2 | — | — |
inadequate effectiveness of this vaccine to prevent pneumococcal infections/child with 2 PPSV23 doses, serotype 22F; Literature Report. This literature marketed report has been received from the authors of a published literature article, titled as stated above and refers to a child patient of unknown age and gender. The patient's medical history was not reported. The patient's concurrent conditions included Sickle Cell Disease. Concomitant therapies were not reported. On an unknown date, the patient was vaccinated with Pneumococcal Vaccine, Polyvalent (23-valent) (manufacturer unknown), Injection, dose number 1, (exact dosage, anatomical location, route of administration, lot # and expiration date were not reported) as prophylaxis. On an unknown date, the patient was vaccinated with Pneumococcal Vaccine, Polyvalent (23-valent) (manufacturer unknown), Injection, dose number 2, (exact dosage, anatomical location, route of administration, lot # and expiration date were not reported) as prophylaxis. On an unknown date, the patient experienced inadequate effectiveness of this vaccine to prevent pneumococcal infections/child with 2 PPSV23 doses, serotype 22F (vaccination failure). At the reporting time, the outcome was unknown. The action taken with Pneumococcal Vaccine, Polyvalent (23-valent) (manufacturer unknown) was reported as not applicable. The reporter considered the event to be related to Pneumococcal Vaccine, Polyvalent (23-valent) (manufacturer unknown). A copy of the published article is attached as further documentation of the patient's experience. This is one of 5 reports from the same reporter.
Sickle cell disease